A novel formulation of ibuprofen sodium (IBUNa) is absorbed faster than (but to a similar extent to) standard ibuprofen (IBU) in healthy subjects; a clinical study found it to provide faster pain relief than standard IBU formulations in subjects with dental pain.

IBUNa has a pharmacokinetic profile similar to that of other faster-absorbed formulations of IBU.

All IBU formulations were well tolerated, most adverse events were mild in nature, and no significant safety findings were noted.